Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals shows a slight decrease today, losing -€0.120 (-0.650%) compared to yesterday.
The stock is one of the favorites of our community with 34 Buy predictions and 1 Sell predictions.
With a target price of 28 € there is a hugely positive potential of 52.05% for Acadia Pharmaceuticals compared to the current price of 18.42 €.
Our community identified positive and negative aspects for Acadia Pharmaceuticals stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Acadia Pharmaceuticals stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | -0.650% | -3.689% | -4.557% | 47.045% | -20.211% | 9.675% | 8.202% |
| Ligand Pharmaceuticals | 1.140% | -2.235% | -4.372% | 90.217% | 5.422% | 153.623% | 34.564% |
| United Therapeutics | 0.760% | -0.429% | 3.615% | 96.730% | 14.042% | 134.957% | 184.971% |
| Ionis Pharmaceuticals Inc. | 1.150% | -1.110% | -0.804% | 169.073% | -5.650% | 87.980% | 80.264% |
Comments
ACADIA Pharmaceuticals (ACAD) was upgraded by Bank of America Corporation from "neutral" to "buy". They now have a $29.00 price target on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its price target raised by JPMorgan Chase & Co. from $31.00 to $34.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its price target raised by TD Cowen from $35.00 to $37.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat